One of the areas addressed by the Cardio-Oncology Research Group of the Centre for Personalized Oncology of the WCRC for Personalized Medicine is to identify a risk group for cardiotoxic effects of antitumor therapy in cancer patients.
To date, the mechanisms of cardiovascular complications have been well studied for anthracyclines. The spectrum of complications induced by these anticancer drugs includes progressive heart failure and rhythm and conduction disturbances in the so-called anthracycline cardiomyopathy, which requires the use of developed early detection algorithms and in some cases even the withdrawal of chemotherapy drugs.
Immune checkpoint inhibitors (ICTs) are relatively new anticancer drugs. They can restart the antitumor immune response and induce tumor cell death by various signaling molecules (Fig. A).
For more read the news of the WCRC for Personalized Medicine.